Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associated infectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey.

Recent Milestones
edit

Tobira Therapeutics received $31M in Series B funding. (9/29/10)

Posted 9/30/10 at 8:50pm via tobiratherapeutics.com
Tobira Therapeutics added Andrew Hindman as President & CEO.

Posted 4/4/11 at 7:54pm
Tobira Therapeutics added Caroline Loewy as EVP & CEO.

Posted 9/10/12 at 7:09pm
Tobira Therapeutics added James Sapirstein as President & CEO.

Posted 9/30/10 at 8:50pm
Tobira Therapeutics added Eckard Weber as Founding CEO.

Posted 5/21/13 at 11:56pm